

LEUKEMIA TREATMENT REGIMENS: Acute Myeloid Leukemia (AML) (Part 1 of 3)

Clinical Trials: The NCCN recommends cancer patient participation in clinical trials as the gold standard for treatment.

Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced healthcare team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are only provided to supplement the latest treatment strategies.

These Guidelines are a work in progress that may be refined as often as new significant data becomes available. The NCCN Guidelines® are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.

Induction Therapy¹

Note: All recommendations are Category 2A unless otherwise indicated.

REGIMEN	DOSING
Age <60 years ²⁻⁵	<p>Days 1-3: An anthracycline (daunorubicin 90mg/m² continuous IV, OR idarubicin 12mg/m²),</p> <p>Days 1-7: Cytarabine 100-200mg/m² continuous IV (Category 1).</p> <p>OR</p> <p>Days 1-3: Daunorubicin 60mg/m² continuous IV,</p> <p>Days 1-7: Cytarabine 200mg/m² continuous IV,</p> <p>Days 1-5: Cladribine 5 mg/m² (Category 1).</p> <p>OR</p> <p>Days 1-3: An anthracycline (daunorubicin 60mg/m² continuous IV, OR idarubicin 12mg/m²),</p> <p>Days 1-6: High-dose cytarabine 2g/m² IV every 12 hours, OR</p> <p>Days 1-4: High-dose cytarabine 3g/m² IV every 12 hours (Category 1 for patients ≤45 years, category 2B for other age groups).</p>
Age ≥60 years ⁶⁻¹⁰ Performance Status 0-2 Favorable cytogenetic markers without prior MDS/Therapy-related AML	<p>Days 1-3: An anthracycline (daunorubicin 45-90mg/m² continuous IV, OR idarubicin 12mg/m² IV (preferred), OR mitoxantrone 12mg/m² IV),</p> <p>Days 1-7: Cytarabine 100-200mg/m² continuous IV.</p> <p>OR</p> <p>Low-intensity therapy</p> <p>Days 1-10: Cytarabine 20mg SC twice daily, OR</p> <p>Days 1-7: 5-azacytidine 75mg/m² IV every 28 days, OR</p> <p>Days 1-5: Decitabine 20mg/m² IV for a 4-week cycle.</p>
Age ≥60 years ^{6,7,9,10} Performance Status 0-2 Unfavorable cytogenetic markers with prior MDS/Therapy-related AML	<p>Low-intensity therapy</p> <p>Days 1-7: 5-azacytidine 75mg/m² IV every 28 days, OR</p> <p>Days 1-5: Decitabine 20mg/m² IV for a 4-week cycle.</p> <p>OR</p> <p>Days 1-3: An anthracycline (daunorubicin 45-60mg/m² continuous IV, OR idarubicin 12mg/m² IV (preferred), OR mitoxantrone 12mg/m² IV),</p> <p>Days 1-7: Cytarabine 100-200mg/m² continuous IV.</p>
Age ≥60 years ⁸⁻¹¹ Performance Status >2 or 0-3 with significant comorbidities or age ≥75 years	<p>Low-intensity therapy</p> <p>Days 1-10: Cytarabine 20mg SC twice daily, OR</p> <p>Days 1-7: 5-azacytidine 75mg/m² IV every 28 days, OR Days 1-5: Decitabine 20mg/m² IV every 28 days.</p> <p>OR</p> <p>Hydroxyurea 10-70mg/kg/day orally in divided doses.</p>

Post-Remission Therapy¹

Age <60 years ^{12,13} Better-risk cytogenetics or molecular abnormalities	<p>Days 1, 3, and 5: High-dose cytarabine 3g/m² IV every 12 hours for 3-4 cycles (Category 1).</p> <p>OR</p> <p>1-2 cycles of high-dose cytarabine-based consolidation followed by autologous hematopoietic stem cell transplant (HSCT) (Category 2B).</p>
Age <60 years ^{12,13} Intermediate-risk cytogenetics or molecular abnormalities	<p>Days 1, 3, and 5: High-dose cytarabine 1.5-3g/m² IV every 12 hours for 3-4 cycles.</p> <p>OR</p> <p>Matched sibling or unrelated donor HSCT.</p>
Age <60 years Treatment-related disease or poor-risk cytogenetics or molecular abnormalities	<p>Matched sibling or unrelated donor HSCT.</p>

continued

LEUKEMIA TREATMENT REGIMENS: Acute Myeloid Leukemia (AML) (Part 2 of 3)

Post-Remission Therapy¹ (continued)

REGIMEN	DOSING
Age ≥60 years Complete Response	Cytarabine 100–200mg/m ² IV for 5–7 days for 1–2 cycles, ± anthracycline (idarubicin or daunorubicin). OR Cytarabine 1–1.5g/m ² IV for 4–6 doses for 1–2 cycles for patients. OR Continue low-intensity regimens (5-azacytidine, decitabine) every 4–6 weeks until progression. OR Reduced intensity HSCT.
Age ≥60 years Induction Failure	Reduced-intensity HSCT in context of clinical trial OR Best supportive care

Salvage Therapy¹

Age <60 years Early Relapse (<12 months)	Salvage chemotherapy* followed by matched sibling or alternative donor HSCT.
Age <60 years Late Relapse (>12 months)	Salvage chemotherapy* followed by matched sibling or alternative donor HSCT. OR Repeat initial successful induction regimen.
Age ≥60 years Early Relapse (<12 months)	Salvage chemotherapy* followed by matched sibling or alternative donor HSCT. OR Best supportive care
Age ≥60 years Late Relapse (>12 months)	Repeat initial successful regimen. OR Salvage chemotherapy* followed by matched sibling or alternative donor HSCT. OR Best supportive care

*Salvage Chemotherapy Options^{8-10, 14-19}

Aggressive therapy for appropriate patients:

Days 1–5: Cladribine 5mg/m² IV,

Days 1–5: Cytarabine 2g/m² IV,

Days 0–5: Granulocyte-colony stimulating factor (G-CSF) 300mcg SC

Days 1–3: Mitoxantrone 10mg/m² IV, **OR** idarubicin 10mg/m² IV.

OR

High-dose cytarabine (if not previously used in treatment) ± anthracycline.

OR

Days 1–5: Fludarabine 30mg/m² IV over 0.5 hours,

Days 1–5: Cytarabine 2g/m² IV over 4 hours,

Days 0 to polymorphonuclear recovery (>0.5 x 10⁹/L): G-CSF 5mcg/kg or 300mcg/m². (G-CSF may also start on Day +6 until engraftment.)

±

Days 1–3: Idarubicin 10mg/m² IV.

OR

Days 1–6: Etoposide 80mg/m² IV over 1 hour,

Days 1–6: Cytarabine 1g/m² IV over 6 hours.

±

Days 1–6: Mitoxantrone 6mg/m² IV bolus.

OR

Days 1–5: Clofarabine 25mg/m² IV,

Days 2–6: Cytarabine 2g/m² IV,

Days 0 to neutrophil recovery: G-CSF 5mcg/kg/day.

Less aggressive therapy:

Days 1–10: Cytarabine 20mg SC twice daily

OR

Days 1–7: 5-azacytidine 75mg/m² IV every 28 days, **OR** **Days 1–5:** Decitabine 20mg/m² IV every 28 days.

OR

Days 1–7: 5-azacytidine 75mg/m² IV every 28 days, **OR** **Days 1–5:** Decitabine 20mg/m² IV every 28 days, **plus** sorafenib for FLT3-ITD mutations

continued

LEUKEMIA TREATMENT REGIMENS: Acute Myeloid Leukemia (AML) (Part 3 of 3)

References

1. NCCN Clinical Practice Guidelines in Oncology™. Acute Myeloid Leukemia. v1.2015. Available at: http://www.nccn.org/professionals/physician_gls/pdf/aml.pdf. Accessed June 24, 2015.
2. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. *N Engl J Med*. 2009;361:1249-1259.
3. Kern W, Estey EH. High-dose cytarabine arabinoside in the treatment of acute myeloid leukemia review of three randomized trials. *Cancer*. 2006;107:116-124.
4. Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. *Blood*. 1996;88:2841-2851.
5. Bishop JF, Matthews JP, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. *Blood*. 1996;87:1710-1717.
6. Krug U, Röhlrig C, Koschmieder A, et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. *Lancet*. 2010;376:2000-2008.
7. Löwenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. *N Engl J Med*. 2009;361:1235-1248.
8. Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. *Cancer*. 2007;109:1114-1124.
9. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. *Lancet Oncol*. 2009;10:223-232.
10. Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. *J Clin Oncol*. 2010;28:556-561.
11. Kantarjian HM, Erba HP, Claxton D, et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. *J Clin Oncol*. 2010;28:549-555.
12. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. *N Engl J Med*. 1994;331:896-903.
13. Löwenberg B, Pabst T, Vellenga E, et al. Cytarabine dose for acute myeloid leukemia. *N Engl J Med*. 2011;364:1027-1036.
14. Martin MG, Welch JS, Augustin K, et al. Cladribine in the treatment of acute myeloid leukemia: a single-institution experience. *Clin Lymphoma Myeloma*. 2009;9:298-301.
15. Montillo M, Mirto S, Petti MC, et al. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. *Am J Hematol*. 1998;58:105-109.
16. Parker JE, Pagliuca A, Mijovic A, et al. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. *Br J Haematol*. 1997;99:939-944.
17. Amadori S, Arcese W, Isacchi G, et al. Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. *J Clin Oncol*. 1991;9:1210-1214.
18. Becker PS, Kantarjian HM, Appelbaum FR, et al. Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapse and refractory acute myeloid leukaemia. *Br J Haematol*. 2011;155:182-189.
19. Ravandi F, Alattar ML, Grunwald, MR, et al. Phase 2 study of azacitidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. *Blood*. 2013;121:4655-4662.

(Revised 6/2015)

© 2015 by Haymarket Media, Inc.